Elicio Therapeutics, Inc. Investigation
Company: Elicio Therapeutics, Inc.
Ticker: (NASDAQ) ELTX
Join the Elicio Therapeutics, Inc. Investigation
Investigation Details
On June 9, the Company reported Q1 2026 earnings showing zero revenue and a widening net loss driven by R&D spending. Six days later, shares collapsed.
The Q1 2026 filing showed the Company generated no product revenue while reporting increased research and development expenses tied to the AMPLIFY-7P program. The Company's cash position funded operations centered on ELI-002 7P as its lead pipeline candidate. On June 15, the 144-patient Phase 2 trial missed its pre-specified primary endpoint.
Days before the trial data became public, B. Riley Securities had issued a Buy rating with a $27 price target on June 10-11. The stock closed at only $4.08 after the Phase 2 miss was disclosed on June 15.